Examine the challenges in India's pharmaceutical R&D ecosystem and assess how schemes like PRIP address them.

India is the "pharmacy of the world" in volume, yet its strength rests on cost-competitive generic manufacturing rather than original innovation. The National Policy on R&D and Innovation in Pharma-MedTech (2023) and the PRIP scheme were launched precisely to close this innovation deficit [1].

Challenges in the R&D ecosystem

• Cost-based, low-value-added model: activity is concentrated in formulations and process chemistry; few new chemical entities emerge, keeping India low in the global value chain [2].
• Weak research infrastructure and translational gap: discovery-stage facilities are thin and academia–industry linkages poor, so laboratory work rarely reaches commercialisation [2].
• Import dependence for bulk drugs/APIs and high-end medical devices, a strategic vulnerability exposed during the pandemic and central to the Atmanirbhar Bharat push in pharma [3].
• Financing gap for small innovators: long gestation and high failure risk deter private capital, excluding MSMEs and startups from serious R&D.
• Weak innovation governance: unclear IP and benefit-sharing terms in publicly funded research dampen participation.

How PRIP responds

• A ₹5,000 crore Central Sector Scheme of the Department of Pharmaceuticals supporting about 300 projects and catalysing roughly ₹11,000 crore of total R&D investment [4].
• Seven Centres of Excellence at NIPERs (₹700 crore) build shared discovery infrastructure and research talent, attacking the translational gap [2].
• De-risking capital: early-stage MSME/startup projects up to ₹9 crore get assistance up to ₹5 crore; later-stage projects up to ₹100 crore [4].
• Targeted priority areas — new medicines, complex generics, biosimilars, novel medical devices — steer funding toward value-chain upgrading rather than generic replication [4].
• Adaptive design: the amended guidelines and second, fully digital call for applications improved governance and benefit-sharing clarity [4][5].

PRIP thus converts a diagnosis of India's innovation deficit into targeted, risk-sharing public investment. Its success will depend on complementary reforms in clinical-trial capacity and regulatory approvals, so that funded research reaches patients. Sustained, PRIP can help India graduate from the world's low-cost supplier to a genuine originator of affordable medicines, advancing both self-reliance and SDG-3.